En vivo
FierceBiotechLilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitorsWatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn LaFierceBiotechMcKesson swaps minority stake in surgical unit to Apollo Funds for $1.25BFierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BBioWorldAppointments and advancements for April 22, 2026BioWorldFinancings for April 22, 2026BioWorldIn the clinic for April 22, 2026BioWorldOther news to note for April 22, 2026BioWorldRegulatory actions for April 22, 2026Thermo FisherGlobal Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation - PR Newswire
Endpoints News 10 feb 2026

AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back

AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back

Original
Contenido no disponible. Consulta la fuente original.